Dechra Pharmaceuticals PLC (DPH) is a leading drug manufacturers-general business based in the UK. In the week up to 9 January Dechra Pharmaceuticals shares plunged 19.25% to a closing position of 4300p. However, over the last 12 months, Dechra Pharmaceuticals's share price has risen by 46.50% from 3662p. Dechra Pharmaceuticals is listed on the London Stock Exchange (LSE) and employs 1,699 staff. All prices are listed in pence sterling.
Best for
Low-cost
Best for
Beginners
Best for
Funds
Best for
Range of markets
Since the stock market crash that started in February 2020, Dechra Pharmaceuticals's share price has had significant positive movement.
Its last market close was 4126p, which is 32.14% up on its pre-crash value of 2800p and 103.25% up on the lowest point reached during the March 2020 crash when the shares fell as low as 2030p.
If you had bought £1,000 worth of Dechra Pharmaceuticals shares at the start of February 2020, those shares would have been worth £855.36 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,470.51.
| Open | 5270p |
|---|---|
| High | 5405p |
| Low | 5245p |
| Close | 5365p |
| Previous close | 5320p |
| Change | 45p |
| Change % | 0.8459% |
| Volume | 202,890 |
| 52-week range | 3235.8151p - 5524.6844p |
|---|---|
| 50-day moving average | 4984.02p |
| 200-day moving average | 4637.215p |
| Wall St. target price | 5152p |
| PE ratio | 82.8628 |
| Dividend yield | 40.5p (0.96%) |
| Earnings per share (TTM) | 51p |
Other fees apply. Your capital is at risk.
Share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|
|
£0 | $10 | £0.00 £268.25 total |
Capital at risk |
 |
£0 | £0.01 | £1.79 £270.04 total |
Capital at risk |
|
£0 | £250 | £8.00 £276.25 total |
Capital at risk |
 |
£0 | £1 | £11.95 £280.20 total |
Capital at risk |
|
£9.99 per month | No minimum | £7.99 £276.24 total |
Capital at risk |
 |
£0 | No minimum | £0.00 £268.25 total |
Capital at risk |
 |
£36 per year | £20 | £9.50 £277.75 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Dechra Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 83x. In other words, Dechra Pharmaceuticals shares trade at around 83x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Dechra Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £123 million.
The EBITDA is a measure of a Dechra Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | £608 million |
|---|---|
| Operating margin TTM | 14.31% |
| Gross profit TTM | £345.9 million |
| Return on assets TTM | 4.44% |
| Return on equity TTM | 8.74% |
| Profit margin | 9.13% |
| Book value | 5.849p |
| Market capitalisation | £4.6 billion |
TTM: trailing 12 months
Dividend yield: 0.96% of stock value
Forward annual dividend yield: 0.96% of stock value
Dividend payout ratio: 79.41% of net profits
Dechra Pharmaceuticals has recently paid out dividends equivalent to 0.96% of its share value annually.
Dechra Pharmaceuticals has paid out, on average, around 79.41% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.96% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 0.96% return on their shares, in the form of dividend payments. In Dechra Pharmaceuticals's case, that would currently equate to about 40.5p per share.
Dechra Pharmaceuticals's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 27 October 2021 (the "ex-dividend date").
Dechra Pharmaceuticals's shares were split on a 1208:1095 basis on 29 April 2012. So if you had owned 1095 shares the day before before the split, the next day you'd have owned 1208 shares. This wouldn't directly have changed the overall worth of your Dechra Pharmaceuticals shares – just the quantity. However, indirectly, the new 9.4% lower share price could have impacted the market appetite for Dechra Pharmaceuticals shares which in turn could have impacted Dechra Pharmaceuticals's share price.
Over the last 12 months, Dechra Pharmaceuticals's shares have ranged in value from as little as 3235.8151p up to 5524.6844p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Dechra Pharmaceuticals's is 0.4662. This would suggest that Dechra Pharmaceuticals's shares are less volatile than average (for this exchange).
Subscribe to trending stock alerts for a chance to win
Ever wondered how to buy shares in Banco Bilbao Vizcaya Argentaria? We explain how and compare a range of providers that can give you access to many brands, including BBVA.
Ever wondered how to buy shares in Bone Biologics? We explain how and compare a range of providers that can give you access to many brands, including Bone Biologics.
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
Everything we know about the Polestar IPO, plus information on how to buy shares.
Ever wondered how to buy shares in STAG Industrial? We explain how and compare a range of providers that can give you access to many brands, including STAG Industrial.
Ever wondered how to buy shares in Vector Group? We explain how and compare a range of providers that can give you access to many brands, including Vector Group.
Ever wondered how to buy shares in Society Pass? We explain how and compare a range of providers that can give you access to many brands, including Society Pass.
Ever wondered how to buy shares in Kaixin Auto? We explain how and compare a range of providers that can give you access to many brands, including Kaixin Auto.
Ever wondered how to buy shares in ZIM Integrated Shipping Services? We explain how and compare a range of providers that can give you access to many brands, including ZIM Integrated Shipping Services.
Ever wondered how to buy shares in Bank of Nova Scotia? We explain how and compare a range of providers that can give you access to many brands, including The Bank of Nova Scotia.
